Trulieve Cannabis (TRLV): Is the $15 Level in Sight?
Key Takeaways
- The central question is whether Trulieve Cannabis Corp. (TRLV) can climb to a $15 price target, the lowest point of the current analyst range and a round-number milestone above its 52-week high.
- The strongest bullish factors include Trulieve's status as the first U.S. cannabis company listed on the New York Stock Exchange, strong cash generation, and federal rescheduling of medical marijuana to Schedule III.
- The biggest risks are ongoing regulatory uncertainty, a net-loss bottom line, and a volatile share price that has swung sharply within a wide 52-week range.
- The resistance level at the 52-week high near $13.28 must be cleared before $15 becomes realistic, while recent support has formed in the roughly $9–10 area.
- Analysts remain broadly constructive, with a consensus average target of about $18, but reaching $15 still requires roughly 35%–40% upside from recent prices.
- Investors should weigh the favorable sentiment against execution and regulatory risks rather than treating $15 as an assured outcome.
Why $15 Is the Level Investors Are Watching
Trulieve Cannabis Corp. has quickly become one of the most closely followed names in the U.S. cannabis sector after making history in mid-2026 as the first domestic marijuana company to list on the New York Stock Exchange. That uplisting, which followed the federal rescheduling of medical cannabis to Schedule III, drew a wave of fresh analyst coverage. Notably, Cantor Fitzgerald initiated coverage with an Overweight rating and a $15 price target, and $15 also represents the low end of the broader analyst range, which spans roughly $15 to $21. For investors searching for a realistic near-term objective, $15 sits just above the stock's 52-week high and stands out as a natural psychological milestone.
Company Overview and Current Market Position
Trulieve is a Florida-based, vertically integrated medical cannabis operator that cultivates, processes, and sells its products through its own dispensaries and home delivery. It operates across states including Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. The company generated about $1.18 billion in revenue in 2025 and reported second-quarter 2026 revenue of roughly $271 million, with adjusted earnings per share (EPS) of $0.11 that beat consensus estimates of $0.03.
Fundamentals remain mixed. Trulieve delivered a 60% gross margin and reported operating cash flow of approximately $109 million and free cash flow of about $74 million in the first half of 2026, but it still posts a net loss and carries no dividend. The shares, with a market capitalization near $2.1 billion, have traded in a wide 52-week range of approximately $4.62 to $13.28, reflecting the sector's elevated volatility.
What Could Drive the Next Leg Higher
Several catalysts support the case for a move toward $15. The NYSE listing meaningfully expanded Trulieve's institutional investor base and improved its access to capital, a step that historically accompanies higher valuations. The Schedule III rescheduling removes a major overhang for U.S. cannabis operators by easing certain tax and banking constraints. Trulieve's continued expansion, including the launch of Georgia's expanded medical program, provides a growth runway, while a recently announced share repurchase program signals management confidence in the company's value. Positive free cash flow also distinguishes Trulieve from many peers that continue to burn cash. From what I see, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Prevent the Move
The path to $15 is not without obstacles. Despite improving operations, Trulieve remains unprofitable on a net-income basis, and the company's financial forecasts suggest revenue may decline modestly in the near term. The broader cannabis industry still faces fragmented state-level regulation and uncertainty over the pace of further federal reform. The stock's high beta and wide trading range mean sharp drawdowns can occur quickly, and any setback in Florida's market dynamics—Trulieve's most important state—could pressure sentiment. Clearing the prior high near $13.28 will require sustained buying interest and continued execution.
Analyst Opinions and Price Targets
Wall Street's view is decidedly optimistic. According to data aggregators, analysts polled by S&P Global rate Trulieve a consensus Strong Buy, with an average 12-month price target of roughly $18.18. Individual targets range from $15 (Cantor Fitzgerald) to $21, with firms such as Alliance Global Partners and Canaccord Genuity carrying $20 targets and Roth MKM at $19. This means the $15 milestone sits comfortably below the consensus forecast, suggesting most analysts see it as an achievable interim level rather than a stretch goal.
Technical Levels That Matter
From a technical perspective, the 52-week high near $13.28 is the first major resistance level that must be overcome before $15 enters play. Because $15 is also a round, psychologically significant number that sits above all recent trading, it is likely to attract selling pressure from investors looking to lock in gains. On the downside, the $9–10 zone has served as recent support, with the 52-week low near $4.62 marking the extreme risk level. The stock's overall trend remains constructive after its uplisting-driven rally, but the distance between current prices and $15 still requires roughly one-third to two-fifths of additional upside. I’m watching this closely as the resistance test unfolds.
Final Assessment
Trulieve reaching $15 is a plausible but not guaranteed outcome. The strongest supporting factors—the historic NYSE listing, Schedule III rescheduling, positive free cash flow, and a consensus analyst target well above $15—suggest the stock has a credible foundation for further gains. However, the primary risks, including persistent net losses, regulatory uncertainty, and the need to clear the $13.28 prior high, cannot be ignored. Investors should monitor quarterly execution, cash-flow trends, and any developments in federal cannabis policy as the key signals for whether the $15 price target becomes achievable in the months ahead.
Using Tickeron AI Daily Buy/Sell Signals
For traders monitoring whether Trulieve can sustain momentum toward higher levels, I rely on Tickeron’s AI Daily Buy/Sell Signals as a data-driven way to track shifting conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. In my view, these signals help me discover new opportunities, monitor existing positions, and identify changing market trends more efficiently than manual screening alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TRLV sees MACD Histogram just turned negative
TRLV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 34 instances where the indicator turned negative. In 31 of the 34 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for TRLV moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 25 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRLV as a result. In 71 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
TRLV moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TRLV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in 190 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 112 of 140 cases where TRLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.096) is normal, around the industry mean (43.873). P/E Ratio (120.482) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement